Search research articles
Contact Us
Filters
Showing results (101-110 of 161) with videos related to
Page
of 17
Sort By:
European Urology Oncology
|
October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy
Karim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
European Urology Oncology
|
September 6, 2023
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer
Sofie H Tolmeijer, Sandra van Wilpe, Maartje J Geerlings, et al.
International Journal of Cancer
|
September 23, 2020
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer
Peter H J Slootbeek, Marleen L Duizer, Maarten J van der Doelen, et al.
Frontiers in Nuclear Medicine
|
October 2, 2024
An Update to the Pilot Study of <sup>177</sup>Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer
Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Oncoimmunology
|
July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
Sandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
International Journal of Cancer
|
October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol
Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 161) with videos related to
Sort By:
Page
of 17
European Urology Oncology
|
October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy
Karim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
European Urology Oncology
|
September 6, 2023
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer
Sofie H Tolmeijer, Sandra van Wilpe, Maartje J Geerlings, et al.
International Journal of Cancer
|
September 23, 2020
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer
Peter H J Slootbeek, Marleen L Duizer, Maarten J van der Doelen, et al.
Frontiers in Nuclear Medicine
|
October 2, 2024
An Update to the Pilot Study of <sup>177</sup>Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer
Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Oncoimmunology
|
July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
Sandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
International Journal of Cancer
|
October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol
Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
Page
of 17